Difficulty: Medium
Average Score: 80%
Practice
A genetic variation in how the metabolite of the cancer drug irinotecan SN-38 is inactivated by the body may lead to:
Correct answer
B
Rationale
UGT1A1 mutations slow SN-38 inactivation, raising neutropenia risk , not affecting efficacy or activation .